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Abstract
Metastatic spread is the most important life-threatening feature of colorectal cancer and is supposed to be mainly driven by
alterations in different carcinogenic pathways. The present study compared mutation and expression profiles of distinctive
biomarkers in colorectal cancer patients with different clinical metastatic patterns. As for a case-control study, patients were
matched according to T category, grading and primary tumour site. Overall, 246 patients with either exclusive lung metastasis (N
= 82), exclusive liver metastasis (N = 82) or non-metastatic colorectal cancer (N = 82) were identified. Paraffin-embedded
specimens were examined for mutations in the RAS and RAF genes and for the expression of β-catenin and CD133. Clinical
endpoints were presence or absence of distant metastasis, formation of metastasis in lungs versus the liver and survival. MAPK
pathway mutations in either the KRAS, NRAS or BRAF gene were associated with the development of lung metastasis (63.4%)
compared to the control group (47.6%; p = 0.04). MAPK pathway alterations plus high β-catenin expression were associated
with metastasis to the lungs but not to the liver (28.0% vs. 13.4%; p = 0.02). High CD133 expression correlated with the
development of liver metastasis compared to the control group (30.5% vs. 14.6%; p = 0.02). This data indicates that different
patterns of distant spread are associated with specific biomarker alterations and may represent different molecular subtypes of
colorectal cancer. However, underlying mechanisms of metastasis formation in different anatomic sites remains unclear. Since
knowledge of the anticipated site of distant spread would substantially impact clinical management, further research is needed to
identify solid biomarkers for different metastatic patterns.
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Introduction
Organ metastasis is still the leading cause of death in the
majority of colorectal cancer (CRC) patients. Prognosis great-
ly differs inter-individually and crucially depends—inter-
alia—on metastatic patterns [1]. Organs most commonly af-
fected are the liver (50–70%) and lungs (10–30%) [2]. Today,
management of metastatic CRC (mCRC) includes multidisci-
plinary approaches combining surgery, systemic therapy and
local ablative techniques in order to provide personalized
treatment procedures [3–6]. Thus, a reasonable effort was
put into the identification of prognostic markers for predicting
the clinical course and individual prognosis of patients with
mCRC [7–9]. The RAS and BRAFmutational status as well as
the mismatch repair (MMR) status represent acknowledged
biomarkers in mCRC patients as they have a prognostic im-
pact and influence systemic treatment [10–12]. Besides its
prognostic and predictive relevance, the RASmutational status
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was shown to impact the metastatic phenotype in mCRC [13].
Whilst the presence of a RAS mutation seems to constitute an
independent risk factor for the development of lung, brain and
bone metastasis, RAS wild-type tumours are associated with
the presence of liver metastasis [14–18].
However, apart from these analyses, no established bio-
markers exist for predicting the formation of metastasis in the
lungs or the liver to date. In previous studies, our group dem-
onstrated that the expression of CD133 and, in particular, the
combined expression of CD133 and β-catenin, both associated
with the Wnt-/β-catenin-pathway and stem cell features of tu-
mour cells, significantly correlates with poor prognosis as well
as the formation of distant metastasis in the liver [19–21].
Further analyses revealed that the expression of these markers
did not correlate with the presence of peritoneal carcinomatosis
or brain metastasis [22, 23]. We hypothesized that different
mechanisms must play a role in the development of cavitary
metastasis, brain metastasis and metastases in the liver. On that
basis, the question arose whether both markers could also play
a crucial role in the development of pulmonary metastasis.
Within the present study, we examined CRC specimens
from patients with exclusive lung metastasis (PUL group)
and exclusive liver metastasis (HEP group) and compared
them with tumours deriving from patients without distant me-
tastases that served as the control group (M0 group). Based on
the data from the literature and the results from our study
group, we focused on the investigation of single biomarkers
consisting of MAP kinase pathway mutations as well as β-
catenin and CD133 expression status and analyzed their im-
pact on the formation of lung or liver metastasis and survival.
Furthermore, the association of different biomarker combina-
tions with different localizations of distant metastases was
evaluated.
As most data in the literature is deducted from retrospective-
exploratory analyses or epidemiological studies, we specifical-
ly chose a case-control format as study design in order to elim-
inate competing for confounding factors by matching all study




All patients involved in the present analysis were diagnosed at
the Institute of Pathology, Faculty of Medicine, LMU
Munich, and subsequently identified via systematic database
search in collaboration with the Munich Cancer Registry
(MCR). The MCR covers an estimated population of mean-
while 4.9 million inhabitants in the southern part of Germany.
Search items comprised “colorectal cancer” and “exclusive
lung metastasis” (for the creation of the PUL group),
“colorectal cancer” and “exclusive liver metastasis” (for the
generation of the HEP group) and “colorectal cancer” and “no
organ metastasis” and “no local recurrence” within 5 years
after first CRC diagnosis (for the formation of the M0 group).
Patients with a histologically proven diagnosis of CRC and
the histological or radiological diagnosis of lung or liver me-
tastasis reported to the MCR between 1998 and 2017 were
considered for the PUL or HEP group, respectively. As a
control, the M0 group consisting of CRC patients with non-
metastatic disease reported to the MCR between 1998 and
2012 was assembled. By halting the recruitment of patients
for the M0 group in 2012, non-metastatic and recurrence-free
survival during a follow-up period of at least 5 years was
ensured. Available patient and tumour characteristics as well
as survival data were collected. Patients with secondary ma-
lignancies were excluded.
Study design
Amatched-pair analysis was deemed appropriate for the pres-
ent investigation. Patients from all groups were matched ac-
cording to pT category, grading and primary tumour site. As
suitable for a matched-pair analysis, all groups consisted of
equal patient numbers. Availability of sufficient analyzable
tumour tissue limited patient numbers to 82 patients per group
(Online Resource 1).
Immunohistochemistry
For immunohistochemistry, 5-μm whole-tissue sections of
formalin-fixed and paraffin-embedded (FFPE) tumour sam-
ples were stained employing a Ventana Benchmark
(Ventana Medical Systems, Oro Valley, AZ) following the
manufacturer’s instructions. A detailed description of antibod-
ies and protocols used in this study is provided in Online
Resource 2. To exclude unspecific reactions of antibodies
and/or reagents, isotype and system controls were performed.
Scoring of immunohistochemistry
All samples were evaluated independently by two investiga-
tors (J.N. and F.T.), both blinded for the clinical outcome. In
case of discrepancy, samples were jointly reviewed and a con-
sensus was reached. A staining score for nuclear expression of
β-catenin was based on the quantity of stained tumour cell
nuclei throughout the whole tumour, whereas the intensity
of staining was not considered (Fig. 1a and b). The score
was as follows: 0, negative; 1+, < 30%; 2+, 30–60%; 3+, >
60% positive cells. Subsequently, the cases were classified
into low (scores 0 and 1) and high-grade (scores 2 and 3)
expression. For CD133, protein expression was defined as
either staining of apical membranous parts of the cells or of
shed cellular debris in the tumour glands. CD133 expression
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levels were scored as low grade (< 50% of positive tumour
glands, Fig. 1c) or high grade (≥ 50% positive tumour glands,
Fig. 1d). Aberrant expression of p53 was defined as strong
diffuse nuclear staining in > 90% of tumour cells (Fig. 1e) or
complete absence of p53 expression in all tumour cells (Fig.
1f). A regulated p53 expression pattern is shown in Fig. 1g.
Loss of MLH1 and MSH2 expression (reflecting a dMMR)
was recorded when nuclear staining was absent in malignant
cells but preserved in the stroma cells or normal epithelial
cells, respectively. Cases with preserved nuclear MLH1 and
MSH2 expression in tumour cells were classified as cases with
proficient MMR status (Fig. 1h–j).
Mutation analysis
For enrichment of tumour tissue, H&E-stained histological
serial sections were inspected and areas containing tumour
cells were defined and marked. These sections were used as
blueprints for transferring the marked areas onto unstained
dewaxed tissue sections. Then, marked areas were microdis-
sected under microscopic control using scalpel blades. From
the resulting tissue, DNA was isolated using QIAamp® DNA
Micro Kit (Qiagen, Hilden, Germany) following the user’s
handbook. For the detection of BRAF, KRAS and NRAS mu-
tations, pyrosequencing was employed. Briefly, HotStarTaq®
Polymerase (Qiagen, Hilden, Germany) was used together
with 1 × PCR buffer (1.5 mM MgCl2), 200 μM dNTPs and
400-nM primers applying optimized PCR conditions (Online
Resource 3). PCR products were analyzed using PyroMark®
Gold Q24 kits (Qiagen, Hilden, Germany) together with
0.3 μM of the corresponding sequencing primer (Online
Resource 3) employing the PyroMark® Q24 device
(Qiagen, Hilden, Germany). Finally, data were analyzed ap-
plying the PyroMark® Q24 software (Qiagen, Hilden,
Germany).
Statistical analysis
For comparison of patient and tumour characteristics between
groups, a two-sided χ2 test was used. Only “age” as a metric
and not normally distributed variable was tested with the
Kruskal–Wallis test (global p) and the Mann–Whitney U test
(PUL vs. HEP). For global testing and head-to-head compar-
isons, the significance of correlations of single biomarkers and
biomarker combinations was calculated using a χ2 test.
Survival analysis for overall and progression-free survival
was assessed using the Kaplan–Meier method and univariate
survival distributions were compared using the log-rank test.
Multivariate logistic regression analysis was performed in or-
der to rule out confounding factors between groups. For mul-
tivariate analysis, the factors “age”, “lymph node status” (N0
vs. N+), “MAP kinase status”, “MMR status”, “p53 expres-
sion status”, “beta-catenin expression status” and “CD133
expression status” were considered. For all statistical tests,
the SPSS V. 26.0 Software (IBM Inc., Armonk, NY) was
employed. A p value lower than 5% (p < 0.05) was considered
statistically significant.
Results
Patient and tumour characteristics
The entire study population consisted of 246 patients (145
male (59%), 101 female (41%)) with histologically proven
adenocarcinoma of the colorectum and exclusive lung metas-
tasis (PUL; N = 82), exclusive liver metastasis (HEP; N = 82)
or non-metastatic disease (M0; N = 82). Baseline patient de-
mographics and tumour characteristics of the analyzed patient
cohort are presented in Table 1 and Online Resource 4.
Patients differed between groups in a few non-matching var-
iables such as gender, primary tumour site and pN category
(global p). However, when comparing only patients with ex-
clusive lung versus exclusive liver metastasis (PUL vs. HEP),
baseline characteristics were equally distributed.
Median age at first CRC diagnosis was significantly higher
in patients of the M0 group compared to the PUL and HEP
groups (71.3 vs. 64.4 vs. 63.5 years; global p < 0.001). A
higher proportion of patients from the M0 group presented
with a primary tumour located in the colon (51 (62.2%)),
whereas in the PUL and the HEP group, the majority of pri-
maries was found in the rectum (50 (61.0%) and 40 (48.8%))
(global p < 0.001). Detailed subgroup analysis showed that
more patients from the PUL group had their primary in the
rectum compared to the M0 group (p < 0.001) and also more
cases with rectal primaries were found in the HEP group com-
pared to the M0 group (p = 0.01). No significant difference
with regard to the primary tumour site was detected between
the PUL and the HEP group (p = 0.29). Also, the temporal
occurrence of metastasis was significantly different between
groups. Whilst the majority of liver metastasis occurred syn-
chronously (59 (72.0%)), lung metastasis was detected syn-
chronously and metachronously in nearly equal parts (42
(51.2%) and 40 (48.8%); p = 0.002 for PUL vs. HEP).
Frequency of single-biomarker alterations according
to metastatic status
For each patient group, all detected MAP kinase (MAPK)
pathwaymutations and immunohistochemical expression pro-
files of CD133, β-catenin and p53 are listed in Table 2.
Analyzed MAPK pathway alterations included the RAS mu-
tational status of the KRAS and NRAS hotspots in exons 2, 3
and 4 as well as the BRAF V600 mutational status and other
BRAF mutations. In decreasing order of frequency, MAPK
pathway alterations were detected in the PUL (52 (63.4%)),
Virchows Arch
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HEP (42 (51.2%)) and M0 (39 (47.6%)) group (global p =
0.10). Thus, the highest frequency of MAPK pathway muta-
tions was observed in patients with lung metastasis mainly
consisting of RAS mutations (N = 48 (58.5%)) and hereunder
especially of KRAS exon 2 mutations (N = 42 (51.2%)).
Consistently, in the HEP and M0 group, RAS respectively
KRAS exon 2 mutations represented the most common
MAPK pathway mutations (HEP (41 RAS (50.0%) and 38
KRAS exon 2 mutations (46.3%)); M0 (35 RAS (42.7%) and
33 KRAS exon 2 mutations (40.2%)). One patient with liver
metastasis was diagnosed with a double mutation in both the
KRAS exon 3 and the NRAS exon 2, respectively. No differ-
ence in frequencies of NRAS and BRAF mutations was ob-
served between groups (p = 0.60 and p = 0.25, respectively).
Fig. 1 Immunohistochemical analysis in colorectal cancer specimens. a
High nuclearβ-catenin expression; b low nuclear β-catenin expression; c
high CD133 expression; d low CD133 expression; e deregulated p53
expression pattern with diffuse strong nuclear p53 staining; f deregulated
p53 expression pattern with the absence of nuclear p53 expression; g
regulated p53 expression pattern; h positive MLH1-staining (pMMR); i
negative MLH1-staining (dMMR); j positive MSH2-staining (pMMR)
Table 1 Patient and tumour
characteristics of the entire study
population (N = 246)
Total N = 246 PUL N = 82 HEP N = 82 M0 N = 82 P
Global PUL vs HEP
Sex
Female 27 (32.9) 32 (39.0) 42 (51.2) 0.053 0.42
Male 55 (67.1) 50 (61.0) 40 (48.8)
Age at first diagnosis of CRC
Median, years 64.4 63.5 71.3 < 0.001 0.28
≥ 70 years 28 (34.1) 24 (29.3) 46 (56.1) 0.001 0.50
≥ 65 years 39 (47.6) 37 (45.1) 64 (78.0) < 0.001 0.75
< 65 years 43 (52.4) 45 (54.9) 18 (22.0)
Sidedness of primary
Right colon 9 (11.0) 9 (11.0) 9 (11.0) 1.00 1.00
Left colon 73 (89.0) 73 (89.0) 73 (89.0)
Primary tumour site
Colon 25 (30.5) 32 (39.0) 51 (62.2) < 0.001 0.29
Rectosigmoid 7 (8.5) 10 (12.2) 7 (8.5)
Rectum 50 (61.0) 40 (48.8) 24 (29.3)
Grading
Low grade (G1, G2) 54 (65.9) 56 (68.3) 56 (68.3) 0.97 0.59
High grade (G3) 27 (32.9) 26 (31.7) 26 (31.7)
Unknown 1 (1.2) - -
pT stage
pT0 2 (2.4) - -
pT1 3 (3.7) 4 (4.9) 4 (4.9)
pT2 11 (13.4) 11 (13.4) 8 (9.8) 0.50 0.49
pT3 57 (69.5) 58 (70.7) 60 (73.2)
pT4 7 (8.5) 9 (11.0) 10 (12.2)
Unknown 2 (2.4) - -
pN status
pN0 32 (39.0) 31 (37.8) 52 (63.4)
pN1 31 (37.8) 37 (45.1) 26 (31.7) 0.001 0.14
pN2 14 (17.1) 14 (17.1) 3 (3.7)
Unknown 5 (6.1) - 1 (1.2)
Time of metastasis
Metachronous 42 (51.2) 23 (28.0) NA - 0.002
Synchronous 40 (48.8) 59 (72.0) NA
For each category, absolute patient numbers are given and percentages in brackets. NA not applicable
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Regarding the stem cell marker CD133, high immunohis-
tochemical expression was most frequently detected in pa-
tients with liver metastasis (N = 25 (30.5%)), nearly reaching
the level of significance in comparison with the PUL and M0
group (p = 0.05). Immunohistochemical detection of nuclear
ß-catenin expression representing an active Wnt/β-catenin
pathway did not reveal significant differences between groups
as a single biomarker. The p53 status did not differ
significantly between groups and was even considered almost
identical. Seven out of 246 patients (2.9%) showed deficient
mismatch repair status (dMMR). Most of them were found in
the M0 group (N = 4/82 (4.9%)) followed by the HEP (N = 2/
82 (2.4%)) and the PUL group (N = 1/82 (1.2%)). In the
metastatic group (HEP and PUL), two out of three patients
showed mutations in the BRAF gene, whereas no mutations in
the analyzed RAS genes could be obtained. One out of two
Table 2 Frequency of MAP kinase mutations and immunohistochemical expressions of CD133, beta-catenin and p53 comparing the three patient
cohorts
Total N = 246 PUL N = 82 HEP N = 82 M0 N = 82 Global P
MAP kinase mutational status
MAP kinase mutation 133 52 (63.4) 42 (51.2) 39 (47.6) 0.10
MAP kinase wild type 113 30 (36.6) 40 (48.8) 43 (52.4)
RAS mutation 124 48 (58.5) 41 (50.0) 35 (42.7) 0.13
RAS wild type 122 34 (41.5) 41 (50.0) 47 (57.3)
KRAS mutation 117 46 (56.1) 38 (46.3) 33 (40.2) 0.12
Exon 2 103 42 (51.2) 33 (40.2) 28 (34.1)
Exon 3 8 1 (1.2) 4 (4.9)# 3 (3.7)
Exon 4 6 3 (3.7) 1 (1.2) 2 (2.4)
KRAS wild type 129 36 (43.9) 44 (53.7) 49 (59.8)
NRAS mutation 8 2 (2.4) 4 (4.9) 2 (2.4) 0.60
Exon 2 5 1 (1.2) 2 (2.4)# 2 (2.4)
Exon 3 3 1 (1.2) 2 (2.4) -
Exon 4 - - - -
NRAS wild type 238 80 (97.6) 78 (95.1) 80 (97.6)
BRAF mutation 9 4 (4.9) 1 (1.2) 4 (4.9) 0.35
V600E 8 4 (4.9) 1 (1.2) 3 (3.7)
Other 1 - - 1 (1.2)
BRAF wild type 237 78 (95.1) 81 (98.8) 78 (95.1)
Stem cell marker
CD133 high 57 20 (24.4) 25 (30.5) 12 (14.6) 0.05
CD133 low 189 62 (75.6) 57 (69.5) 70 (85.4)
Wnt pathway
β-catenin high 109 41 (50.0) 33 (40.2) 35 (42.7) 0.43
β-catenin low 137 41 (50.0) 49 (59.8) 47 (57.3)
p53 pathway
p53 regulated 80 28 (34.2) 24 (29.3) 28 (34.2) 0.74
p53 deregulated 166 54 (65.8) 58 (70.7) 54 (65.8)
MMR status
pMMR 239 81 (98.8) 80 (97.6) 78 (95.1) 0.36
dMMR 7 1 (1.2) 2 (2.4) 4 (4.9)
Marker combinations* Positive Negative Positive Negative Positive Negative
MAP kinase mutational status PLUS β-catenin expression 23 (28.0) 59 (72.0) 11 (13.4) 71 (86.6) 14 (17.1) 68 (82.9) 0.048
MAP kinase mutational status PLUS CD133 expression 15 (18.3) 67 (81.7) 17 (20.7) 65 (79.3) 5 (6.1) 77 (93.9) 0.02
β-catenin expression PLUS CD133 expression 9 (11.0) 73 (89.0) 10 (12.2) 72 (87.8) 8 (9.8) 74 (90.2) 0.88
For each category, absolute patient numbers are given and percentages in brackets. Significant p values are printed in italics
*Positive is defined as both markers being positive (positive for MAP kinase mutational status is defined as the presence of a mutation; positive for β-
catenin and CD133 expression is defined as a high expression). Negative is defined as one of the markers or both markers being negative (negative for
MAP kinase mutational status is defined as wild type; negative for β-catenin and CD133 expression is defined as a low expression)
# One case with a double mutation in KRAS Exon 3 and NRAS Exon 2
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BRAF-mutated cases showed combined overexpression of
CD133, the other case showed a coincidence of deregulated
p53 status and deregulated CD133 status. In the M0 cohort
with dMMR status, two BRAF-mutated cases were found, one
of them with combined deregulated p53 status. One case
showed exclusive BRAF mutation and one case exhibited
combined β-catenin and CD133 expression. One patient
showed no alterations in the analyzed pathways. Taken to-
gether, no distinct pattern of altered biomarkers or biomarker
combinations could be obtained and due to low patient num-
bers, no level of statistical significance was obtained in the
global analysis (p = 0.36) or head-to-head comparisons
(Table 3).
Multivariate analysis adjusting results for the most relevant
confounders (age, lymph node status (N0 vs. N+), MAP ki-
nase status, MMR status, p53, beta-catenin and CD133) con-
firmed the independent association between the investigated
markers and metastatic patterns (Online Resource 5).
Biomarker combinations associated with the
formation of metastasis in the lungs or the liver
When taking into account the abundance of biomarker com-
binations instead of single biomarkers, patients with exclusive
lung metastasis (PUL group) were characterized by the pres-
ence of both a MAPK pathway mutation plus a high Wnt/β-
catenin expression (N = 23 (28.0%)), whereas a larger propor-
tion of patients from the HEP and M0 group showed negativ-
ity for one or both markers (global p = 0.048; PUL vs. HEP p
= 0.02; Tables 2 and 3). Furthermore, MAPK pathway muta-
tions in combination with high CD133 expression correlated
with the development of metastasis in general compared to a
non-metastatic course of the disease (M1 (PUL N = 15
(18.3%) and HEP N = 17 (20.7%)) vs. M0 N = 5 (6.1%); p
= 0.01) (Table 3). Head-to-head comparisons of all groups
according to single biomarkers and biomarker combinations
as well as corresponding p values are summarized in Table 3.
Frequencies and coincidence of alterations according to met-
astatic status are illustrated in Fig. 2a. Figure 2b gives an
overview of the extracted results.
Survival data according to biomarker profiles
According to biomarker profiles, survival analyses comparing
overall survival (OS) and progression-free survival (PFS) of
patients from the PUL versus the HEP group were performed.
For OS analysis, 53 of 82 patients from the PUL group and 56
of 82 patients from the HEP group were available. For PFS, 77
of 82 patients from each the HEP and the PUL group were
available.
Overall, patients with lung metastasis showed a longer OS
and PFS than patients with liver metastasis (OS: 65.7 vs. 37.1
months, HR 1.41 [95%CI: 0.96–2.06], p = 0.08; PFS: 23.9 vs.
16.1 months, HR 1.45 [95% CI: 1.06–2.00], p = 0.02) (Online
Resource 6 and Online Resource 7).
In both the PUL and the HEP group, the presence of a
MAPK pathway mutation was associated with inferior OS
(PUL: 51.5 vs. 83.6 months, HR 1.96 [95% CI: 1.07–3.60],
p = 0.03; HEP: 26.4 vs. 46.3 months, HR 1.93 [95%CI: 1.13–
3.29], p = 0.02) and PFS (PUL: 19.0 vs. 28.8 months, HR 1.99
[95% CI: 1.18–3.35], p = 0.01; HEP: 10.1 vs. 19.1 months,
HR 1.53 [95% CI: 0.97–2.42], p = 0.07) compared to patients
without MAPK pathway mutations. This effect stayed signif-
icant when comparing patients with and without MAPK path-
way mutations between groups (OS: global p = 0.004, PFS:
global p = 0.002) (Online Resource 6 and Online Resource 8).
Within the PUL group, the different marker combinations
consisting of MAPK pathway mutations and CD133 expres-
sion status were associated with significant differences in OS
and PFS. In patients with lung metastasis and a MAPK path-
way mutation plus a high CD133 expression, both OS and
PFS were significantly shorter than in patients with either
Table 3 Head-to-head
comparisons between groups











MAP kinase mutational status 0.15 0.04 0.64 0.11
CD133 expression 0.03 0.12 0.02 0.38
β-catenin expression 0.72 0.35 0.75 0.21
MMR status 0.18 0.17 0.41 0.56
Marker combinations
MAP kinase mutational status PLUS β-catenin
expression
0.50 0.09 0.52 0.02
MAP kinase mutational status PLUS CD133
expression
0.01 0.02 0.01 0.69
β-catenin expression PLUS CD133 expression 0.67 0.80 0.62 0.81
Significant p values are printed in italics
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MAP kinase wild-type tumours and/or low CD133 expression
(OS: 48.1 vs. 67.4 months, HR 2.37 [95% CI: 1.20–4.67], p =
0.01); PFS: 19.0 vs. 28.5 months, HR 1.86 [95% CI: 1.01–
3.43], p = 0.04) (Online Resource 6).
No survival differences were observed when focusing on
CD133 and β-catenin expression as single biomarkers. Also,
neither the combination of MAPK pathway mutations plus β-
catenin expression status nor the combination of β-catenin
plus CD133 expression status revealed any survival differ-
ences within or between groups.
Discussion and conclusion
There is consensus that colorectal cancer is a heterogeneous
disease. Also, it is widely accepted that tumour biology im-
pacts treatment efficacy and long-term outcome [24–26].
However, when it comes to different metastatic phenotypes,
no reliable biomarkers predicting the formation of distant me-
tastasis exist so far. For clinical management, knowledge
about the CRC patient’s individual risk to metastasize and
the site of distant spread could guide aggressiveness of
(local) treatment and help to stratify patients for personalized
treatment approaches.
Thus, the present study aimed to investigate biomarker
profiles that could predict the development of metastasis in
the lungs or the liver, both pivotal organs and frequently af-
fected by CRC metastasis. Indeed, we were able to identify
biomarker profiles that are associated with different patterns
of distant spread in colorectal cancer. We show that the pres-
ence of a MAPK pathway mutation plus a deregulation of the
Wnt/β-catenin pathway is associated with metastasis to the
lungs indicating that this biomarker combination could predict
a higher risk of lung metastasis. In contrast, the expression of
the stem cell-associated marker CD133 correlated with the
presence of liver metastasis.
The clinical interest to estimate the likelihood of lung or
liver metastasis or a non-metastatic course of disease clearly
lies in follow-up care after local treatment of CRC and early
detection of potentially resectable or locally treatable organ
metastasis. Referring to an easy-to-practice biomarker profile
that predicts the development of metastasis in the liver or the
lungs could enable physicians to perform diagnostic proce-
dures according to the patient’s individual risk and pave the
way for early treatment of organ metastasis. With the MAPK
Fig. 2 a Venn diagram illustrating the frequencies and coincidences of
biomarker alterations according to metastatic status. Numbers indicate
proven alterations which are defined as the presence of a mutation in
the MAP kinase pathway and high immunohistochemical expression of
Wnt/β-catenin and CD133 (see Table 2). b Overview of the relevant
biomarker alterations correlating with the formation of metastasis in the
lungs and/or the liver
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pathway mutations, β-catenin as a representative from the
Wnt/β-catenin-pathway as well as the stem cell marker
CD133, we specifically examined standard biomarkers that
are well established and widely used in routine diagnostics
of CRC specimens.
To accomplish the highest statistical accuracy, we chose a
matched-pair analysis and therefore created a biobank con-
taining clinical data and tumour tissue specimen from 246
CRC patients with exclusive lung metastasis (PUL group),
exclusive liver metastasis (HEP group) or non-metastatic dis-
ease (M0 group). Using this case-control design, patients were
matched according to relevant baseline characteristics as ap-
propriate for a matched-pair analysis to exclude confounding
factors.
With regard to the biological background, CRC develops as a
result of different combinations of genetic alterations, epigenetic
changes and posttranslational modifications [27]. Most CRC
arises through the gradual malignant progression of a benign
precursor lesion known as an adenoma. Themajority of sporadic
CRC arises via the adenoma-carcinoma sequence starting with
mutations of the tumour-suppressor adenomatous polyposis coli
(APC) with subsequent dysregulation of theWnt/β-catenin path-
way [27]. Forced expression of mutant KRAS in CRC enhances
nuclear β-catenin accumulation and increases the levels of Wnt
target genes. This KRAS-induced augmentation of Wnt/β-
catenin activity results in increased proliferation and malignant
progression and therefore is an important driver for the formation
of metastases [28, 29].
In our study, we demonstrate that a combined expression of
β-catenin together with a MAPK pathway mutation correlates
with metastasis to the lungs but not to the liver. Indeed, some
clinical studies described MAP kinase mutations as indepen-
dent risk factors for the development of lung metastasis
[14–17]. We focused on the metastatic route into the lungs
and compared them against the liver and non-metastatic dis-
ease and can clearly disclose a difference in the formation of
metastasis to these organs. Based on the results of Horst and
coworkers, who showed that the enhancement of the Wnt/β-
catenin pathway leads to proliferation and malignant progres-
sion in vitro [29], we observe that this marker combination
correlates with the formation of metastasis in the lungs but not
in the liver.
Investigating the stem cell marker CD133, the subgroup of
patients with liver metastasis showed the highest proportion of
tumours with high CD133 expression compared to patients
with lung metastasis or non-metastatic disease. In detail,
30.5% of patients with exclusive liver metastasis showed
CD133 positivity and the percentage was comparable to pre-
viously reported results from Horst et al. that described 26%
of unselected colorectal tumours as CD133 high and 74% as
CD133 low [30].
Interestingly, the combination of a MAPK pathway muta-
tion plus a high CD133 expression was associated with a
distant spread in general (M0 vs. M1). This finding may be
explained by the fact that the MAPK pathway mutation still
depicts the dominant driver in formation of metastasis. Also,
the combination of nuclear β-catenin expression plus CD133
expression did not reveal any significant association with met-
astatic patterns in the present analysis. This is not necessarily
in contrast to previously published data from our group show-
ing an association between the high expression of CD133 and/
or nuclear β-catenin and a high risk of distant metastases in
right-sided colon cancers [19]. As the majority (89 %) of pri-
maries were left-sided in the present analysis and due to
known differences between left- and right-sided colon can-
cers, data is neither comparable nor transferable.
Furthermore, we present survival data from our study pop-
ulation according to metastatic group. It is acknowledged that
patients with CRC and lung metastasis live longer than those
with other metastatic manifestations [31, 32]. Accordingly, in
the present study, patients with lung metastasis showed longer
OS and PFS than patients with liver metastasis. Furthermore,
the known prognostic value of theMAPK pathwaymutational
status was clearly confirmed indicating that the patient cohort
analyzed was representative of large CRC populations.
Interestingly, no prognostic relevance of the CD133 and β-
catenin expression status was observed thus seeming only
predictive for the formation of metastasis but not decisive
for long-term outcome.
Since most tumours of the investigated patient cohort de-
rived from the left-sided colon and rectum, as expected, only
few patients (2.9%) showed dMMR. Due to low numbers,
statistical comparisons are not reasonable and the relevance
of the MMR status stays unclear for the investigated questions
of the present analysis. In the investigated study cohort, pa-
tients with primary tumours in the rectum were overrepresent-
ed in both metastatic groups (PUL and HEP) compared to the
control group (M0). However, the in-depth analysis revealed
no statistical difference between the PUL and the HEP group.
Thus, results showing significant differences in single-
biomarker alterations as well as biomarker combinations be-
tween these groups appear not to be biased by localization of
the primary tumour. Furthermore, multivariate analysis ruled
out confounding factors for PUL versus HEP patients.
Of interest, previous studies show that KRASmutations are
associated with metastasis to the central nervous system
(CNS) [18, 23]. Thus, CRC patients with haematogenous
spread to the lungs and to the CNS seem to have molecular
features in common that possibly indicate similar carcinogenic
pathways leading to metastasis formation in the lungs and/or
brain. However, underlying mechanisms can certainly not be
derived from the presented results.
The present analysis is certainly limited by its retrospective
and exploratory design as well as data acquisition from a can-
cer registry. Thus, by its nature, the study cannot serve with
results from functional studies or in vivo experiments but
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nevertheless provides interesting information about the pre-
sented biomarker alterations.
Taken together, our data indicate that the enhanced activ-
ity of the Wnt/β-catenin pathway intensified by a MAPK
pathway mutation may play a crucial role in the formation
of lung metastasis, whereas high expression of CD133 cor-
relates with the presence of liver metastasis. Based on these
findings, we raise the hypothesis that the anatomic site of
metastasis formation may depend on different patterns or
varying sequences of molecular marker alterations during
CRC carcinogenesis, respectively. On this basis, we would
like to initiate a discussion on the necessity of a novel and
clinically relevant classification of CRC. Certainly, precise
mechanisms underlying themetastasis formation in different
anatomic still remain unclear. However, knowledge of the
anticipated site of distant metastasis would substantially im-
pact clinical management, so an increased effort into the
identificationof solid biomarkers for organotropic formation
of metastasis is justified.
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